Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia. Researchers will compare OsrHSA to the positive comparator, plasma-derived HSA (pHSA) to see if OsrHSA presents as non-inferior to pHSA in the indication of hypoalbuminemia in hepatic cirrhosis patients. Participants will be randomized in a 1:1 ratio to receive OsrHSA or HpHSA (20g IV qd) for up to 14 days, following an EOT visit. Follow-up visits will be taken on EOT+7d, EOT+14d, and EOT+30d, respectively.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06355479
Study type Interventional
Source Healthgen Biotechnology Corp.
Contact
Status Completed
Phase Phase 3
Start date April 10, 2023
Completion date December 12, 2023

See also
  Status Clinical Trial Phase
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT02138253 - A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Phase 2
Recruiting NCT02652351 - Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis Phase 1
Completed NCT00794482 - Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. Phase 3
Completed NCT00856713 - Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers Phase 1
Completed NCT02163512 - Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Completed NCT00857480 - Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin Phase 1
Completed NCT00006164 - Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Phase 3
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT00698464 - Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Phase 1
Completed NCT02778425 - The Treatment of Hepatocirrhosis and Portal Hypertension N/A
Completed NCT03420768 - A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Phase 2
Completed NCT03445208 - A Study of Experimental Medication BMS-986036 Given to Healthy Participants Phase 1
Completed NCT03804593 - HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
Completed NCT03712280 - MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Phase 2
Completed NCT02230683 - A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Phase 2
Completed NCT02230670 - A Study of IDN-6556 in Subjects With Liver Cirrhosis Phase 2
Completed NCT01135628 - Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy N/A